SCHEMBL6113243

SCHEMBL6113243

Cc1ccc(C(=O)I)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.65
CES2 O00748 3/20 0.65
CES1 P23141 3/20 0.65
LMNA P02545 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.62
TDP1 Q9NUW8 4/20 0.56
HTT P42858 3/20 0.56
NPSR1 Q6W5P4 3/20 0.56
KMT2A Q03164 3/20 0.56
PKM P14618 2/20 0.56
ATM Q13315 2/20 0.56
HPGD P15428 2/20 0.56
MEN1 O00255 2/20 0.56
NLRP1 Q9C000 1/20 0.56
GAA P10253 1/20 0.56
NTSR1 P30989 1/20 0.56
SRD5A2 P31213 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
GSK3B P49841 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL815029 0.84 TSHR (0.50) ALDH1A1CES2CES1LMNAHTT
SCHEMBL822185 0.79 ALDH1A1 (1.00) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL8218963 0.79 ALDH1A1 (0.52) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL167254 0.79 CES2 (1.00) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL52200 0.79 ALDH1A1 (1.00) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL13896026 0.79 ALDH1A1 (0.52) ALDH1A1CES2CES1LMNASMN1; SMN2
4-Methylbenzoic Acid SCHEMBL6914164 0.78 CA1 (0.61) ALDH1A1CES2CES1LMNASMN1; SMN2
Terephthalic Acid SCHEMBL526449 0.77 ALDH1A1 (1.00) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL55409 0.77 SMN1; SMN2 (0.74) ALDH1A1CES2CES1LMNASMN1; SMN2
4-Methylbenzoic Acid SCHEMBL93638 0.77 ALDH1A1 (1.00) ALDH1A1CES2CES1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110698404-A Preparation method of high-purity celecoxib 安徽恒星制药有限公司 2020-01-17 CN claimed
WO-2021121420-A1 BENZOPYRAZOLE COMPOUND AND INTERMEDIATE, PREPARATION METHOD, AND APPLICATION THEREOF 江苏凯迪恩医药科技有限公司 2021-06-24 WO disclosed
WO-2020252396-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS CIDARA THERAPEUTICS, INC. (US) 2020-12-17 WO disclosed
CN-110698404-A Preparation method of high-purity celecoxib 安徽恒星制药有限公司 2020-01-17 CN disclosed
CN-103833723-B The manufacture method of cyclic sulfonic acid ester and intermediate thereof 和光纯药工业株式会社 2016-08-17 CN disclosed
EP-2757102-B1 Intermediate for producing a cyclic sulfonic acid ester WAKO PURE CHEM IND LTD (JP) 2016-03-23 EP disclosed
US-8969591-B2 Method for producing cyclic sulfonic acid ester and intermediate thereof WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2015-03-03 US disclosed
EP-2463281-B1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF WAKO PURE CHEM IND LTD (JP) 2014-10-22 EP disclosed
WO-2014163055-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTRICITY STORAGE DEVICE USING SAME 宇部興産株式会社 (JP) 2014-10-09 WO disclosed
EP-2757102-A1 1,3-propanesultone derivative useful in the preparation of a 1,3-propenesultone derivative Wako Pure Chemical Industries, Ltd. (JP) 2014-07-23 EP disclosed
US-20140142324-A1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2014-05-22 US disclosed
US-8673963-B2 Method for producing cyclic sulfonic acid ester and intermediate thereof WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2014-03-18 US disclosed
WO-2014037313-A1 USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2014-03-13 WO disclosed
CN-102471305-B Process for producing cyclic sulfonic acid ester and intermediate thereof WAKO PURE CHEM IND LTD 2014-01-29 CN disclosed
US-20130188120-A1 COMPOUND HAVING PHOTOSENSITIVITY, POLYMER FORMED BY POLYMERIZING THE COMPOUND, AND PRODUCTION METHOD THEREOF INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) 2013-07-25 US disclosed
EP-2463281-A1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF Wako Pure Chemical Industries, Ltd. (JP) 2012-06-13 EP disclosed
US-20120130089-A1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2012-05-24 US disclosed
EP-2027107-B1 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2012-02-15 EP disclosed
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed
WO-2009074504-A2 SYNTHESIS OF DYES IN MIXING UNITS BASF SE (DE) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142324-A1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF STS, TST, SULT1A1 ALDH1A1 131/4885CES2 540/4885CES1 153/4885
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof ANXA1, ANXA5, ANXA2 ALDH1A1 1020/4885CES2 4794/4885CES1 2448/4885
US-20120130089-A1 METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF STS, TST, SULT1A1 ALDH1A1 131/4885CES2 540/4885CES1 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.